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ABSTRACT
The coincidence of thyroid ophthalmopathy and 
ocular myasthenia gravis is a defined but rather 
rare condition.
A 30-year-old female patient was admitted with 
complaints of weight loss, sweating, palpitation 
and tremor of both hands for about 4 months. 
She was diagnosed as having Graves' disease 
with elevated thyroid hormone levels, diffuse 
hyperplastic thyroid gland with increased iodine, 
131 uptake and positive antithyroid antibodies. 
Two months after the diagnosis of thyroid 
disease, she developed diplopia and in the 
following days, bilateral ptosis. Orbital magnetic 
resonance imaging showed that the lateral and 
inferior rectus muscles were thickened indicating 
the infiltration of those muscles. She had positive 
response to the prostigmine test and elevated 
acetylcholine receptor antibody levels supporting 
the diagnosis of myasthenia gravis. She had 
undergone tymectomy and the pathology 
specimen revealed thymic hyperplasia.
This case demonstrates the comorbidity of 
thyroid ophthalmoplegia and ocular myasthenia 
gravis. Ocular involvement by this two different
pathologies is a rare condition but should be 
taken into consideration.
K ey  W o rd s : Myasthenia gravis, Graves’ 
disease, Ophthalmopathy, Ocular involvement, 
Thyrotoxicosis, Thymectomy
INTRODUCTION
Graves’ disease and myasthenia gravis are both 
autoimmune diseases and the coexistence of 
these two diseases is well recognised. 
Myasthenia Gravis is more frequent in patients 
with thyroid disease. It is seen in less than one 
percent of patients with Graves’ disease, and 
approximately five percent of myasthenic 
patients are thyrotoxic at some time (1). 
Moreover thyroid diseases occur more frequently 
in close relatives of patients with myasthenia 
gravis than in the general population (2). 
Antithyroglobulin and antimicrosomal antibodies 
have been reported to be present in 11% and 
27% of myasthenic patients, respectively (3). 
Conversely, 51% of thyrotoxic non-myasthenic 
patients have been shown to have circulating 
antibodies against thyroid, smooth muscle and
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thymus gland (3). If these two clinical conditions 
coexist in a patient, both present with their 
characteristic signs and symptoms. Here we 
present a case of thyroid ophthalmopathy and 
isolated ocular myasthenia gravis.
CASE REPORT
A thirty-year-old, right-handed woman was 
admitted with the complaints of weight loss, 
sweating, palpitation and tremulousness 
continuing for about 4 months. The patient was 
diagnosed as having Graves’ disease. The 
findings were: diffuse enlarged thyroid gland, 
elevated thyroid hormone levels, positive 
antithyroid antibodies, and increased iodine 131 
uptake. Propylthiouracil 300 mg/day was started. 
Two months after the diagnosis of thyroid 
disease she developed diplopia on downward 
and lateral gazes. Three weeks later, bilateral 
ptosis was added to the symptoms. The severity 
of her ptosis fluctuated during day time. Her 
medical history revealed that, she had had a 
cesarian section 10 months before the 
appearence of the symptoms.
The patient was examined three days after the 
onset of ptosis. In physical examination, she had 
a diffusely palpable thyroid gland and 
exophthalmos of both eyes (right eye 24mm 
Hertel, left eye 22mm Hertel). The neurological 
examination revealed bilateral ptosis 
predominantly on the right side (Fig. 1). Diplopia 
occurred during horizontal and downward gazes. 
The right globe was restricted during downward 
gaze (Fig. 2). The severity of ptosis was 
increased after sustained upward gaze. Both lids
F ig .2  : Downward gaze showing the restriction of the right eye
exceeded the limbus 3mm and the pupilla was 
covered by the median line.
The routine laboratory investigations including 
blood glucose level, erythrocyte sedimentation 
rate, electrolytes, kidney and liver function tests 
were normal. Complete hemogram was 
consistent with mild iron deficiency anemia. 
Thyroid function tests revealed free T3: 10,19 
pmol/L (Normal values:3,5-6,5), free T4: 31,84 
pmol/L (Normal values:11,5-23,2), TSH: 0,01 
mlU/ml (Normal values:0,35-5,5). Investigation of 
thyroid antibodies revealed Anti-M: 1020 IU/ml 
(Normal values:0-50), Anti-Tg: 17,7 IU/ml 
(Normal values:0-50), Tr Ab: 49 IU/ml (Normal 
values:0-15).
Magnetic resonance imaging (MRI) of the globes 
showed increased intensity and thickening of 
both lateral rectus, right medial rectus, right 
superior rectus and left inferior rectus muscles, 
indicating the infiltration of these muscles, which 
was consistent with thyroid ophthalmopathy.
Ptosis showed significant improvement after the 
intramuscular injection of 1,5 mg neostigmine 
methylsulphate, but the restriction of eye 
movements did not change. Repetitive 
stimulation of the right ulnar nerve-adductor digiti 
minimi muscle and facial nerve-nasalis muscle 
revealed no decrement. Acetylcholine receptor 
antibody level was found to be 1,30 nmol/L, 
which was more than two times higher than the 
normal levels (Normal values:0-0,50). Thorax 
computed tomography revealed a mass lesion of 
6x3x2 cm located in the thymus zone.
F i g . i  s Primary position showing bilateral ptosis After two months of propylthiouracil treatment,
the patient became euthyroid. Pyridostigmine 60
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mg four times daily was added for the treatment 
of ptosis. In spite of medication, exophthalmos 
and exophthalmic ophthalmoplegia were not 
relieved, but ptosis responded to the treatment. 
After two sessions of plasmapheresis, the patient 
was operated on. Total thyroidectomy and 
extended thymectomy were performed.
Pathological examination was relevant with 
thymic hyperplasia. After the operation, the 
patient’s medication included 60 mg
pyridostigmine four times daily and 0,15 mg 
levothyroxine sodium daily. Under this
medication, her ophthalmoparesis continued, but 
the ptosis was fairly controlled.
DISCUSSION
Myasthenia gravis (MG) is an autoimmune 
disease characterized by impaired 
neuromuscular transmission due to circulating 
antiacetylcholine receptor autoantibodies The 
clinical expression of MG varies, ranging from a 
mild localized disease such as ocular MG (OMG) 
to a severe generalized disease (GMG) (4).
Patients with MG may have evidence of
coexisting autoimmune thyroid diseases (AITD), 
which include autoimmune thyroiditis and 
Graves’ disease (5). Epidemiological studies 
showed that AITD occur in approximately 5-10% 
of MG patients, whereas a fairly low incidence of 
MG, (0.2%) has been reported in patients with 
AITD (6). The clinical presentation of MG 
associated with AITD is frequently restricted to 
the eye muscles. GMG was found to be more 
frequent in patients without thyroid disease. Also, 
thymic abnormalities were less frequent in MG 
associated with AITD than in MG without thyroid 
autoimmunity. Although this is not true for the 
patient who had thymic hyperplasia, a greater 
frequency of thyroid antibodies in OMG, when 
compared to GMG, has been reported (4).
The reason for the association of AITD with OMG 
is unknown, but several hypotheses may be 
considered. First, OMG and GMG might actually 
represent separate diseases (7) with different 
spectra of associated diseases. Second, an 
immunological cross-reactivity against epitopes 
or autoantigens shared by the thyroid and the 
eye muscles might be the basis of this 
association (8). A third explanation for the higher
frequency of OMG in AITD could be that these 
disorders have a common genetic background 
(9).
In three-quarters of patients with both conditions, 
thyrotoxic symptoms occur before or 
concurrently with those of myasthenia. Our 
patient had thyrotoxicosis symptoms seven 
months before her ptosis developed (10).
The ocular changes in Graves' disease may 
include exophthalmos, periorbital oedema, lid 
lag, chemosis and ophthalmoplegia. 
Exophthalmic ophthalmoplegia may be 
unilateral, but it is usually bilateral. The 
extraocular muscles most commonly involved 
are the superior and lateral recti (11). In our 
patient, the downward movement of the right eye 
was restricted and the patient was complaining of 
diplopia during downward and horizontal gazes. 
Her diplopia and ophthalmoparesis did not 
change after neostigmine injection, while her 
ptosis improved visibly. The MRI findings 
showing increased intensity and thickening of the 
extraocular eye muscles were consistent with 
thyroid ophthalmopathy.
Two thirds of the patients with both disorders 
show improvement in myasthenia gravis after 
treatment for thyroid disease. In other patients, 
however, the treatment of thyroid disease has no 
effect on myasthenic symptoms (1). The 
treatment of hyperthyroidism has not improved 
the myasthenic symptoms in our patient, since 
her need for anticholinesterase did not decrease. 
Some authors state that, thymectomy may have 
positive effects on the clinical condition of both 
myasthenia (12) and ATID (13). Our patient did 
not show an obvious improvement after 
thymectomy.
In conclusion, MG associated with AITD has a 
mild clinical expression characterized by 
preferential involvement of the eye muscles. This 
is consistent with the hypothesis that OMG and 
GMG are separate diseases with different 
spectra of associated diseases and different 
immunogenetic back-grounds. The association 
of OMG with AITD might also be due to common 
immunopathogenetic mechanisms acting 
through antigens shared by the eye muscles and 
the thyroid. Further immunological and genetic 
studies are needed to verify these hypotheses.
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The important clinical implication of this report is 
that the coexistence of MG with thyroid 
autoimmunity might have prognostic relevance in 
the identification of a subgroup of MG patients 
with a mild form of the disease. It should be 
remembered that, ptosis is not an expected 
symptom in thyroid ophthalmopathy. If ptosis or 
paresis of the orbicularis oculi muscle develop in 
a patient with thyroid ophthalmopathy, 
superimposition of myasthenia gravis should be 
considered.
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